Hilda Li

Cooley advised VISEN Pharmaceuticals, a late-stage, near-commercialization biopharmaceutical company focused on providing treatments for select endocrine diseases in Greater China (including Hong Kong, Macau and Taiwan), on its HK$783 million (approximately US$101 million) initial public offering (IPO) on the Stock Exchange of Hong Kong, subject to the exercise of a 15% overallotment option.

Cooley advised Inmagene Biopharmaceuticals, a privately held, global clinical-stage biotechnology company developing novel therapeutics for immunological and inflammatory diseases, on its definitive merger agreement with Ikena Oncology (Nasdaq: IKNA).

Cooley advised Bitdeer Technologies Group (Nasdaq: BTDR), a world-leading technology company for blockchain and high-performance computing, on its $360 million principal amount of 5.25% convertible senior notes due 2029, which includes the option for initial purchasers to purchase up to an additional $40 million principal amount of notes.

Cooley advised Gracell Biotechnologies, a global clinical-stage biopharmaceutical company dedicated to developing innovative cell therapies for the treatment of cancer and autoimmune diseases, on its definitive agreement to be acquired by AstraZeneca.

Cooley advised Gracell Biotechnologies, a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune diseases, on its private placement financing of up to $150 million.